{"id":385567,"date":"2026-03-14T23:37:08","date_gmt":"2026-03-14T23:37:08","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/385567\/"},"modified":"2026-03-14T23:37:08","modified_gmt":"2026-03-14T23:37:08","slug":"most-insomnia-meds-dont-worsen-sleep-apnea","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/385567\/","title":{"rendered":"Most Insomnia Meds Don&#8217;t Worsen Sleep Apnea"},"content":{"rendered":"<p><strong>Summary: <\/strong>Treating insomnia when a patient also has Obstructive Sleep Apnea (OSA)\u2014a condition known as COMISA\u2014is a delicate balancing act. While sedative-hypnotics can help patients fall asleep, there has long been a fear that these drugs might \u201cover-relax\u201d the airway muscles, worsening apnea events and dropping oxygen levels.<\/p>\n<p>A landmark systematic review and network meta-analysis analyzed 32 randomized controlled trials to determine which medications offer the best sleep architecture without compromising respiratory safety.<\/p>\n<p><strong>Key Facts<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li><strong>The Respiratory Myth:<\/strong> The study found no broad evidence that most hypnotics uniformly worsen respiratory outcomes. Master metrics like the <strong>Apnea-Hypnea Index (AHI)<\/strong> remained stable compared to placebos for most drugs.<\/li>\n<li><strong>The Temazepam Exception:<\/strong> Not all drugs were cleared. <strong>Temazepam<\/strong>, a benzodiazepine, was found to significantly decrease arterial oxygen saturation during sleep, suggesting it may be riskier for OSA patients.<\/li>\n<li><strong>Tailored Treatment:<\/strong> The researchers emphasized that drug selection must be \u201csymptom-specific.\u201d Some patients struggle with falling asleep (sleep onset), while others struggle with waking up too early (sleep maintenance).<\/li>\n<li><strong>CPAP Neutrality:<\/strong> The study accounted for both CPAP users and non-users, ensuring the results are applicable to patients who cannot tolerate breathing machines.<\/li>\n<li><strong>First-of-its-Kind:<\/strong> This is the first network meta-analysis to comprehensively compare multiple hypnotics across both sleep quality and respiratory safety in adults with OSA.<\/li>\n<\/ul>\n<p><strong>Source: <\/strong>Fujita Health University<\/p>\n<p><strong>OSA is a common sleep disorder characterized by oxygen desaturation due to repeated airway collapse during sleep. This leads to oxygen desaturation or awakening from sleep. It is often linked to metabolic problems, cardiovascular disease, and a lower quality of life. OSA and insomnia symptoms often co-occur, a condition known as comorbid insomnia and sleep apnea or COMISA. This can complicate usual treatments like continuous positive airway pressure (CPAP) therapy, which is often recommended for moderate to severe OSA management.<\/strong><\/p>\n<p>Although Clinical Practice Guidelines generally recommend cognitive behavioral therapy for insomnia symptoms in individuals with OSA, medications are often preferred and prescribed in real-world settings. However, concerns remain that some of the common sedative-hypnotics could worsen respiratory parameters and lead to aggravated OSA symptoms.<\/p>\n<p>  <img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/03\/sleep-apnea-neuropharmacology-neuroscience.jpg\" alt=\"This shows a head and pills.\"  \/> New meta-analysis shows that most hypnotic medications can effectively treat insomnia in OSA patients without significantly worsening respiratory metrics or oxygen levels. Credit: Neuroscience News<\/p>\n<p>Recently, researchers from Japan, led by Professor Taro Kishi from the Department of Psychiatry, Fujita Health University School of Medicine, Japan, conducted a systematic review and network meta-analysis to identify the hypnotics providing optimal sleep architecture without compromising the respiratory safety in adults with OSA. Professor Tsuyoshi Kitajima, Professor Nakao Iwata, and Dr. Kenji Sakuma, also from the Department of Psychiatry, Fujita Health University School of Medicine, were a part of the research group.<\/p>\n<p>The study findings were made available online on February 10, 2026, in the academic journal of the Japanese Society of Psychiatry and Neurology,\u00a0Psychiatry and Clinical Neurosciences.<\/p>\n<p>\u201cThe hypnotics used for insomnia in patients with OSA have varied effects on sleep quality and respiratory function. Our research aims to enable safer and more effective drug selection that considers the respiratory risks and is tailored to each patient\u2019s symptoms,\u201d\u00a0mentions Prof. Kishi while talking about the motivation underlying the study.<\/p>\n<p>The researchers conducted a network meta-analysis of 32 randomized controlled trials for 12 types of hypnotic medications, including brotizolam, daridorexant, eszopiclone, flurazepam, lemborexant, nitrazepam, ramelteon, temazepam, triazolam, zaleplon, zolpidem, zopiclone, and placebo.<\/p>\n<p>17 distinct outcomes, categorized into sleep architecture, respiratory function, treatment acceptability, treatment tolerability, and other safety outcomes, were assessed for the study.<\/p>\n<p>The hypnotics showed varied effectiveness in treating insomnia. Highlighting the importance of this finding, Prof. Kitajima mentions,\u00a0\u201cWhile some patients reported difficulty in falling asleep, others reported waking up in the middle of the night or early in the morning. Suggesting appropriate medication, based on the symptom of insomnia, can aid in alleviating the problem effectively.\u201d<\/p>\n<p>Additionally,\u00a0\u201cSince our network meta-analysis included both CPAP users and non-users, we have focused on the sensitivity analysis results while excluding CPAP users and titration studies,\u201d\u00a0Dr. Sakuma emphasized.<\/p>\n<p>The biggest concern for OSA patients when using sleep-inducing medication is the worsening of apnea and hypopnea. Overall, the study did not find broad evidence that hypnotics uniformly worsened respiratory outcomes. Important metrics like apnea-hypopnea index did not significantly differ from placebo for most of the analyzed drugs.<\/p>\n<p>Conversely, temazepam, a benzodiazepine hypnotic, was found to decrease arterial oxygen saturation during sleep. Considering the limitations of this study, clinicians are advised to individualize treatment, carefully weigh potential benefits and risks, and monitor respiratory status when prescribing hypnotics to patients with OSA.<\/p>\n<p>\u201cThis is the first network meta-analysis to comprehensively compare multiple hypnotics across both sleep architecture and respiratory parameters in adults with OSA. This allows us to establish the requirement of tailoring medication based on specific symptoms associated with insomnia.<\/p>\n<p>\u201cClinical trials that verify the effectiveness of each sleeping medication on patients\u2019 specific insomnia symptoms can help in the formal synthesis of subjective outcomes in the future,\u201d concludes Prof. Iwata.<\/p>\n<p><strong>Funding information<\/strong><br \/>This work was supported by JSPS KAKENHI Grant Number 25K10874 (Grant-in-Aid for Scientific Research(C)).<\/p>\n<p>Key Questions Answered:<strong class=\"schema-faq-question\">Q: I have sleep apnea; is it actually safe for me to take a sleeping pill?<\/strong><\/p>\n<p class=\"schema-faq-answer\"><strong>A:<\/strong> According to this massive analysis of 12 different drugs, the answer for most modern hypnotics is \u201cyes.\u201d For a long time, doctors were afraid that sleeping pills would make your tongue and throat muscles so relaxed that your airway would collapse more often. However, this study shows that for most medications, those \u201crespiratory parameters\u201d didn\u2019t actually get worse.<\/p>\n<p><strong class=\"schema-faq-question\">Q: Which medications should I be most careful with?<\/strong><\/p>\n<p class=\"schema-faq-answer\"><strong>A:<\/strong> The study flagged <strong>Temazepam<\/strong> (a benzodiazepine) because it was linked to lower oxygen levels in the blood during sleep. While many other drugs were safe, this finding reinforces that you shouldn\u2019t just grab any sleep aid off the shelf\u2014it needs to be tailored to your specific type of insomnia and your respiratory health.<\/p>\n<p><strong class=\"schema-faq-question\">Q: If the pills are safe, why do doctors still push CPAP machines?<\/strong><\/p>\n<p class=\"schema-faq-answer\"><strong>A:<\/strong> CPAP is the \u201cgold standard\u201d because it physically keeps your airway open. Sleeping pills only treat the symptom (insomnia), not the cause (the airway collapse). However, for people with COMISA who find it impossible to sleep with a mask on, these findings offer a \u201cplan B\u201d to help them get the rest they need without fear of stopping their breathing.<\/p>\n<p>Editorial Notes:<\/p>\n<ul style=\"background-color:#ffffe8\" class=\"wp-block-list has-background\">\n<li>This article was edited by a Neuroscience News editor.<\/li>\n<li>Journal paper reviewed in full.<\/li>\n<li>Additional context added by our staff.<\/li>\n<\/ul>\n<p>About this OSA and neuropharmacology research news<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Author: <\/strong><a href=\"http:\/\/neurosciencenews.com\/cdn-cgi\/l\/email-protection#9af1f5f2f5b7eae8dafceff0f3eefbb7f2efb4fbf9b4f0ea\" type=\"mailto\" id=\"mailto:koho-pr@fujita-hu.ac.jp\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Hisatsugu Koshimizu<\/a><br \/><strong>Source: <\/strong><a href=\"https:\/\/fujita-hu.ac.jp\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Fujita Health University<\/a><br \/><strong>Contact: <\/strong>Hisatsugu Koshimizu \u2013 Fujita Health University<br \/><strong>Image: <\/strong>The image is credited to Neuroscience News<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Original Research: <\/strong>Open access.<br \/>\u201c<a href=\"https:\/\/dx.doi.org\/10.1111\/pcn.70036\" type=\"link\" id=\"http:\/\/dx.doi.org\/10.1111\/pcn.70036\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Comparative effects of hypnotic agents on sleep architecture and respiratory outcomes in obstructive sleep apnea: A systematic review and network meta-analysis<\/a>\u201d by Taro Kishi MD, PhD,\u00a0Toshikazu Ikuta PhD,\u00a0Kenji Sakuma MD, PhD,\u00a0Masakazu Hatano PhD,\u00a0Tatsuhiko Kishi MD,\u00a0Tsuyoshi Kitajima MD, PhD,\u00a0Nakao Iwata MD, PhD. Psychiatry and Clinical Neurosciences<br \/><strong>DOI:10.1111\/pcn.70036<\/strong><\/p>\n<p><strong>Abstract<\/strong><\/p>\n<p><strong>Comparative effects of hypnotic agents on sleep architecture and respiratory outcomes in obstructive sleep apnea: A systematic review and network meta-analysis<\/strong><\/p>\n<p>Aim<\/p>\n<p>This network meta-analysis of randomized controlled trials (RCTs) aimed to investigate which hypnotics are associated with the most favorable sleep architecture and respiratory outcomes in adults with obstructive sleep apnea.<\/p>\n<p>Methods<\/p>\n<p>Primary outcomes included total sleep time (TST) and apnea\u2013hypopnea index (AHI) during TST. Other outcomes were rapid eye movement (REM) sleep time, latency to persistent sleep (LPS), wake after sleep onset (WASO), sleep efficiency (SE), AHI during non-REM or REM sleep, mean peripheral oxygen saturation (SpO2) during TST, mean SpO2\u00a0nadir during TST, arousal index (AI), all-cause discontinuation, adverse event-related discontinuation, and incidence of individual adverse events. Effect sizes with 95% confidence intervals were calculated.<\/p>\n<p>Results<\/p>\n<p>This systematic review included 32 RCTs (n\u2009=\u20091871, average age\u2009=\u200951.60\u2009years, 62.52% male, mean AHI\u2009=\u200923.60). Our network meta-analysis evaluated brotizolam, daridorexant, eszopiclone, flurazepam, lemborexant, nitrazepam, ramelteon, temazepam, triazolam, zaleplon, zolpidem, zopiclone, and placebo. Compared with placebo, lemborexant increased TST, REM sleep time, and SE and decreased LPS and WASO, whereas both daridorexant and zolpidem increased TST and SE and decreased WASO. These three medications demonstrated respiratory safety and discontinuation profiles similar to those of placebo. Eszopiclone increased TST and SE and decreased LPS, WASO, AHI during TST, and AI, but its effects on LPS, WASO, AHI during TST, and AI disappeared in the sensitivity analysis, excluding continuous positive airway pressure titration studies.<\/p>\n<p>Conclusion<\/p>\n<p>Our network meta-analysis identified different effects of various hypnotics on sleep architecture and respiratory parameters; however, the lack of data prevented a formal synthesis of subjective outcomes. Therefore, these results should be interpreted with caution in clinical practice.<\/p>\n","protected":false},"excerpt":{"rendered":"Summary: Treating insomnia when a patient also has Obstructive Sleep Apnea (OSA)\u2014a condition known as COMISA\u2014is a delicate&hellip;\n","protected":false},"author":2,"featured_media":385568,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[274],"tags":[176428,18,176429,135,176430,19,540,17,462,165265,1281,18607,176431,176432,176433,176434],"class_list":["post-385567","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-comisa","tag-eire","tag-fujita-health-university","tag-health","tag-hypnotics","tag-ie","tag-insomnia","tag-ireland","tag-medication","tag-neuropharmacology","tag-neuroscience","tag-obstructive-sleep-apnea","tag-osa","tag-respiratory-safety","tag-sleep-architecture","tag-temazepam"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116230163259433786","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/385567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=385567"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/385567\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/385568"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=385567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=385567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=385567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}